MX2010009873A - Compuesto de pirrol biciclico. - Google Patents

Compuesto de pirrol biciclico.

Info

Publication number
MX2010009873A
MX2010009873A MX2010009873A MX2010009873A MX2010009873A MX 2010009873 A MX2010009873 A MX 2010009873A MX 2010009873 A MX2010009873 A MX 2010009873A MX 2010009873 A MX2010009873 A MX 2010009873A MX 2010009873 A MX2010009873 A MX 2010009873A
Authority
MX
Mexico
Prior art keywords
pyrrole compound
bicyclic pyrrole
disclosed
bicyclic
aminopiperidin
Prior art date
Application number
MX2010009873A
Other languages
English (en)
Inventor
Hiroyuki Nakahira
Yasumitsu Sakurai
Yukihiro Nishio
Original Assignee
Dainippon Sumitomo Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Sumitomo Pharma Co filed Critical Dainippon Sumitomo Pharma Co
Publication of MX2010009873A publication Critical patent/MX2010009873A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se da a conocer un compuesto constituido de una forma de cristal fácilmente manipulable y que tiene estabilidad en el almacenamiento que es suficientemente práctica para utilizarse como ingrediente activo de un producto farmacéutico. Específicamente, se da a conocer el hemihidrato de monoclorhidrato de 6-[(3R)-3-aminopiperidin-1-il]-5-(2-cloro-5-flu orobencil-1,3-dimetil-1H-pirrolo[3,2-d]pirimidin-2,4(3H,5H)-diona .
MX2010009873A 2008-03-10 2009-03-03 Compuesto de pirrol biciclico. MX2010009873A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008059471 2008-03-10
PCT/JP2009/053910 WO2009113423A1 (ja) 2008-03-10 2009-03-03 二環性ピロール化合物

Publications (1)

Publication Number Publication Date
MX2010009873A true MX2010009873A (es) 2010-09-30

Family

ID=41065091

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009873A MX2010009873A (es) 2008-03-10 2009-03-03 Compuesto de pirrol biciclico.

Country Status (12)

Country Link
US (1) US20110009433A1 (es)
EP (1) EP2264034A1 (es)
JP (1) JPWO2009113423A1 (es)
KR (1) KR20100137452A (es)
CN (1) CN101970442A (es)
AU (1) AU2009222696A1 (es)
BR (1) BRPI0908168A2 (es)
CA (1) CA2718252A1 (es)
IL (1) IL208060A0 (es)
MX (1) MX2010009873A (es)
RU (1) RU2010141562A (es)
WO (1) WO2009113423A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN105142621A (zh) 2012-10-24 2015-12-09 国家健康科学研究所 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
EP3273981B1 (en) 2015-03-24 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of diabetes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE388951T1 (de) * 2001-07-03 2008-03-15 Novo Nordisk As Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
JP2005509603A (ja) * 2001-09-19 2005-04-14 ノボ　ノルディスク　アクティーゼルスカブ Ｄｐｐ−ｉｖ酵素の阻害剤であるヘテロ環化合物
JP2003300977A (ja) * 2002-04-10 2003-10-21 Sumitomo Pharmaceut Co Ltd キサンチン誘導体
RU2297418C9 (ru) * 2002-06-06 2009-01-27 Эйсай Ко., Лтд. Новые конденсированные производные имидазола, ингибитор дипептидилпептидазы iv, фармацевтическая композиция, способ лечения и применение на их основе
AU2005320134B2 (en) 2004-12-24 2011-04-28 Dainippon Sumitomo Pharma Co., Ltd. Bicyclic pyrrole derivatives
RU2008129873A (ru) * 2005-12-23 2010-01-27 Новартис АГ (CH) Конденсированные гетероциклические соединения, полезные в качестве ингибиторов дпп-iv
JP2007262040A (ja) 2006-03-30 2007-10-11 Dainippon Sumitomo Pharma Co Ltd ３−置換アミノ環状アミン誘導体の製造方法

Also Published As

Publication number Publication date
JPWO2009113423A1 (ja) 2011-07-21
BRPI0908168A2 (pt) 2015-12-15
EP2264034A1 (en) 2010-12-22
KR20100137452A (ko) 2010-12-30
CN101970442A (zh) 2011-02-09
RU2010141562A (ru) 2012-04-20
CA2718252A1 (en) 2009-09-17
US20110009433A1 (en) 2011-01-13
AU2009222696A1 (en) 2009-09-17
IL208060A0 (en) 2010-12-30
WO2009113423A1 (ja) 2009-09-17

Similar Documents

Publication Publication Date Title
MX2010009873A (es) Compuesto de pirrol biciclico.
CL2011001265A1 (es) Compuestos derivados de 2h-pirazolo[3,4-d]-pirimidin 4,6(5h,7h)- diona, inhibidores de fosfodiesterasa 1 (pde1); composicion farmaceutica; util en el tratamiento de enfermedades que involucran trastornos relacionados con dopamina d1, tales como parkinson, depresion, narcolepsia, esquizofrenia, entre otros.
GEP20156417B (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
MY169791A (en) Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
MD4735B1 (ro) Derivaţi ai pirolo[2,3-d]pirimidinei ca inhibitori de Kinaze Janus-asociate (JAK)
PH12015500666A1 (en) Pyrazolopyrimidine jak inhibitor compounds and methods
NZ706236A (en) Antiviral compounds
MX2021012478A (es) Formas cristalinas de un inhibidor de tirosina quinasa de bruton.
MY170326A (en) Imidazo [1,2-b] pyridazine derivativea as kinase inhibitors
IL210071A (en) Derivatives of {3– (pyrid – 2 – illmethyl) –3 h– [1, 2, 3] triazolo [4, 5 – d] pyrimidine-5-amine}, their pharmaceutical preparations and their use in drug preparation
NZ600430A (en) Spiro-oxindole mdm2 antagonists
EA201001188A1 (ru) Связанные мостиковой связью бициклические гетероциклические или спиробициклические гетероциклические производные пиразоло[1,5-a]пиримидинов, способы их получения и их применения
NZ725585A (en) Processes for preparing jak inhibitors and related intermediate compounds
GEP20156285B (en) Compounds and compositions as trk inhibitors
MX364157B (es) Compuestos de pirazolo [1,5-a] pirimidina sustituidos como inhibidores de trk cinasa.
WO2009151997A8 (en) Process for producing bicycloaniline derivatives
MX348470B (es) Pirimidinas anilladas sustituidas y uso de las mismas.
MX2016008363A (es) Combinaciones farmaceuticas.
TN2015000285A1 (en) Therapeutically active pyrazolo-pyrimidine derivatives
SG193245A1 (en) Crystalline and non- crystalline forms of tofacitinib, and a pharmaceutical composition comprising tofacitinib and a penetration enhancer
GEP20135780B (en) Novel pyrazolo [3,4-d] pyrimidine derivatives as anti-cancer agents
PE20120534A1 (es) PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt
EA201291247A1 (ru) ФАРМАЦЕВТИЧЕСКИЙ СОСТАВ В ФОРМЕ ДВУХСЛОЙНЫХ ТАБЛЕТОК, СОДЕРЖАЩИХ ИНГИБИТОР HMG-CoA РЕДУКТАЗЫ И ИРБЕСАРТАН
MY149157A (en) Weekly administration of dipeptidyl peptidase inhibitors
NZ630580A (en) 6-(4-(1-amino-3-hydroxycyclobutyl)phenyl)-5-phenyl(furo,thieno or pyrrolo) [2, 3-d] pyrimidin-4-one derivatives for the treatment of cancer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal